151P CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with doublet chemotherapy (Nab-PTX & S-1) and apatinib (anti-angiogenic TKI) for the first-line treatment of stage IV gastric cancer (GC)Qian‐Li Xue, Han Liang, B. Wang et al.|Annals of Oncology|2021Cited by 3
Safety and Current Status of the COVID-19 Vaccine among Patients with Breast cancer: A Cross-Sectional Study from ChinaShaohua Zhang, Zefei Jiang, Gang Sun et al.|Infectious Diseases & Immunity|2023Cited by 1